Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

December 13, 2023

https://www.globenewswire.com/news-release/2023/12/13/2795561/0/en/Quoin-Pharmaceuticals-Announces-FDA-Clearance-of-Clinical-Optimization-Plan-for-QRX003-for-Netherton-Syndrome.html

Positive initial data and clean safety profile catalyze optimization plan
Size of both ongoing clinical trials significantly increased
Lower dose eliminated from blinded trial
Dosing frequency changed to twice-daily from once-daily for both trials

Read more at globenewswire.com

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.